← Patent-cliff monitor small molecule CRESEMBA ISAVUCONAZONIUM SULFATE
Loss of exclusivity June 2031 FDA regulatory exclusivity expiry
Drug detail Brand name CRESEMBA Active ingredient ISAVUCONAZONIUM SULFATE Strength 186MG Dosage form CAPSULE Route ORAL Modality Small molecule FDA approval March 2015 Marketing status RX
Listed patents Patent Expires Type 10603280*PED March 2028 — 10206879*PED March 2028 — 10206879 September 2027 product 10603280 September 2027 product 6812238*PED April 2026 — 6812238 October 2025 substance
Regulatory exclusivity Code Expires PED June 2031 ODE-454 December 2030 ODE-458 December 2030 GAIN September 2027 PED June 2027 NPP December 2026 PED September 2022 ODE-90 March 2022 ODE-305 March 2022
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.